Insulet(NASDAQ) PODD

Market Cap$9.94B

Since IPO (2007)+798%

5 Year-51%

1 Year-57%

1 Month-14%

Premium Feature

Moneyball Superscore

81/100

$143.32

-0.04%

-0.06Today

After hours$143.61+$0.29 (+0.20%)

Insulet last closing stock price
Metric	Price	Date
Last close	USD 143.41	2026-08-27

Insulet stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.36%	USD 146.87	2026-08-20
1 month	-14.37%	USD 167.47	2026-07-28
3 month	-1.06%	USD 144.94	2026-05-29
Year to date	-49.55%	USD 284.24	2025-12-31
1 year	-57.11%	USD 334.35	2025-08-27
3 year	-20.86%	USD 181.21	2023-08-28
5 year	-51.4%	USD 295.09	2021-08-27
Since inception	+798.37%	USD 15.96	2007-05-15

Insulet Financials at a Glance

Market Cap

$9.94B

Revenue (TTM)

$3.05B

Net Income (TTM)

$375.30M

EPS (TTM)

$5.04

P/E Ratio

28.42

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$143.32

Volume

1,338,295.145

Open

$142.96

Price

$143.32

Volume

1,338,295.145

Open

$142.96

Previous Close

$143.41

Daily Range

$140.98 - $144.60

52-Week Range

$126.40 - $354.88

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$143.32

Volume

1,338,295.145

Open

$142.96

Previous Close

$143.41

Daily Range

$140.98 - $144.60

52-Week Range

$126.40 - $354.88

Estimated Earnings Date

Nov 5, 2026

PODD News

Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?

Brendan CoffeyAug 24, 2026

Page 1

PODD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Insulet

Insulet Corporation helps people with diabetes manage blood sugar without needles. Its wearable pods deliver insulin automatically through a tubeless system. This technology simplifies daily health routines for patients around the world.

What Does Insulet Make?

Omnipod 5: Automated insulin delivery (AID) system that links with continuous glucose monitors (CGM); serves patients with type 1 and type 2 diabetes.
Omnipod DASH: Bluetooth-enabled insulin management system; uses a touchscreen personal diabetes manager for device control.
Drug Delivery: Specialized pods sold to pharmaceutical partners for non-insulin medications; revenue was $5.8 million in the second quarter of 2026.

Expanding Across Global Borders

Launched Omnipod 5 in five Middle Eastern countries in February 2026.
Released Omnipod 5 and Omnipod Discover in Spain in July 2026.
Advanced the EVOLVE clinical study for a fully closed-loop delivery system for type 2 diabetes.
Invested in a new manufacturing plant in Costa Rica to support global production growth.

Why Insulet Stands Out

Insulet sells its products through pharmacies to help patients avoid large upfront costs. Its patented tubeless design allows for a recurring revenue model as users replace pods every three days.

The Financial Results

Total revenue rose 23.5% to $801.7 million in the three months ended June 30, 2026.
International Omnipod sales grew 35.5% to $251.8 million in the second quarter of 2026.
Gross margin reached 70.2% in the quarter ended June 30, 2026.
Net income was $95.0 million for the three-month period ended June 30, 2026.
Non-GAAP free cash flow hit $145.4 million for the six months ended June 30, 2026.

Bottom Line

Insulet has grown from a specialized device maker into a global provider of automated insulin delivery systems. Its focus on tubeless technology and pharmacy-based distribution supports steady expansion in international markets.

AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

5,400

CEO

Ashley A. McEvoy

Website

www.insulet.com

Headquarters

Acton, MA 01720, US

PODD Financials

Key Financial Metrics (TTM)

Gross Margin

71.08%

Operating Margin

16.89%

Net Income Margin

12.29%

Return on Equity

26.69%

Return on Capital

18.46%

Return on Assets

11.86%

Earnings Yield

3.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.94B

Shares Outstanding

69.35M

Volume

1.34M

Avg. Volume

1.60M

Financials (TTM)

Gross Profit

$2.17B

Operating Income

$515.80M

EBITDA

$636.90M

Operating Cash Flow

$511.20M

Capital Expenditure

-$212.90M

Free Cash Flow

$298.30M

Cash & ST Invst.

$534.90M

Total Debt

$948.40M

Insulet Performance Analysis

Insulet annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,305,300,000	18.8%
2023	2023-12-31	USD 1,697,100,000	30.0%
2024	2024-12-31	USD 2,071,600,000	22.1%
2025	2025-12-31	USD 2,708,100,000	30.7%

Insulet sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	8.8%
Q4	2025-12-31	11.0%
Q1	2026-03-31	-2.8%
Q2	2026-06-30	5.3%

Insulet annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.07	-73.1%
2023	2023-12-31	USD 2.94	4372.6%
2024	2024-12-31	USD 5.78	96.5%
2025	2025-12-31	USD 3.48	-39.9%

Insulet sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	287.5%
Q4	2025-12-31	16.1%
Q1	2026-03-31	-9.7%
Q2	2026-06-30	5.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$801.70M

+23.5%

Gross Profit

$562.60M

+24.4%

Gross Margin

70.18%

N/A

Market Cap

$9.94B

N/A

Market Cap/Employee

$1.84M

N/A

Employees

5,400

N/A

Net Income

$95.00M

+322.2%

EBITDA

$132.20M

+88.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$534.90M

-52.3%

Total Debt

$948.40M

-33.1%

Accounts Receivable

$588.70M

+32.4%

Inventory

$484.80M

+8.5%

Long Term Debt

$929.50M

-1.0%

Short Term Debt

$18.90M

-96.0%

Return on Assets

11.86%

N/A

Return on Invested Capital

21.31%

N/A

Free Cash Flow

$59.40M

-65.7%

Operating Cash Flow

$88.40M

-55.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SNNSmith & Nephew plc

SNNSmith & Nephew plc$29.13-0.58%

ZBHZimmer Biomet Holdings, Inc.

ZBHZimmer Biomet Holdings, Inc.$99.48-1.87%

STESTERIS plc

STESTERIS plc$232.97-1.60%

WSTWest Pharmaceutical Services, Inc.

WSTWest Pharmaceutical Services, Inc.$346.09-1.09%

PHGKoninklijke Philips N.V.

PHGKoninklijke Philips N.V.$26.92-0.26%

DGXQuest Diagnostics Incorporated

DGXQuest Diagnostics Incorporated$244.61-0.16%

LHLabcorp Holdings Inc.

LHLabcorp Holdings Inc.$336.54+0.24%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$227.98+0.09%

INTCIntel

INTCIntel$92.09+0.04%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.78+0.02%

ONDSOndas

ONDSOndas$8.75+0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.31+0.05%

PATHUiPath

PATHUiPath$18.33+0.09%

NOKNokia

NOKNokia$10.59+0.02%

Questions About PODD

What is the current price of Insulet?

Insulet is trading at $143.41 per share.

What is the 52-week range for Insulet?

Over the past 52 weeks, Insulet has traded between $126.40 and $354.88.

How much debt does Insulet have?

As of the most recent reporting period, Insulet reported total debt of $948.40M.

How much cash does Insulet have on hand?

Insulet reported $534.90M in cash and cash equivalents in its most recent financial results.

What is Insulet’s dividend yield?

Insulet does not currently have a dividend yield.

Insulet(NASDAQ) PODD

Insulet Financials at a Glance

PODD News

Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Is Insulet (PODD) the Future of Diabetes Management?

Insulet (PODD) Q2 Revenue Jumps 33%

Why Insulet Stock Was Zooming Higher This Week

Why Shares of Insulet Dropped This Week

Why Insulet Stock Is Sinking Today

Is It Time to Buy the S&P 500's 3 Worst-Performing August Stocks?

PODD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Insulet

What Does Insulet Make?

Expanding Across Global Borders

Why Insulet Stands Out

The Financial Results

Bottom Line

PODD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Insulet Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PODD

What is the current price of Insulet?

What is the 52-week range for Insulet?

How much debt does Insulet have?

How much cash does Insulet have on hand?

What is Insulet’s dividend yield?

Premium Investing Services